Nuvalent Inc (NUVL) Appoints Christy Oliger to its Board

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Christy Oliger to its Board of Directors.

"Christy's proven success in delivering new therapies to patients living with cancer strengthens our Board as we evolve from a development-stage company toward potential commercialization," said James Porter, Ph.D., Chief Executive Officer at Nuvalent. "We welcome her deep expertise and valuable perspective to our team as we prepare for a potential first approval from our pipeline of novel kinase inhibitors in 2026."

Ms. Oliger brings more than 30 years of commercial and business experience in the pharmaceutical and biotechnology industry to the Nuvalent Board. Most recently, Ms. Oliger served as Senior Vice President of the Oncology Business Unit at Genentech, where she was responsible for all commercial activities in the U.S. During her 20-year tenure at Genentech, Ms. Oliger held a number of senior leadership roles in both commercial and research and development across a variety of therapeutic areas, including oncology, neurology, rare disease, respiratory, dermatology and immunology. Prior to Genentech, she held management positions at Schering-Plough.

"Nuvalent's pipeline reflects a focused and disciplined approach to drug development, grounded in rigorous science and a deep understanding of patient and physician needs," said Ms. Oliger. "I believe in the potential of these programs to make a meaningful difference, and look forward to supporting this dedicated team towards achieving its goal of delivering a new generation of precisely targeted therapies to the patients who need them."

You May Also Be Interested In

• Deere conference call: 2027 orders up mid-single digits from last year)
• BJ's Wholesale Club (BJ) call put ratio 1.3 calls to 1 put into quarter results
• Quanome Technologies forms quantum advisory council and network